⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for trametinib

Every month we try and update this database with for trametinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsNCT05668585
Solid Tumors
Melanoma
NSCLC
CRC
ATC
CFT1946
Trametinib
Cetuximab
18 Years - C4 Therapeutics, Inc.
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsNCT05876806
Cancer
Dabrafenib
Trametinib
19 Years - Seoul St. Mary's Hospital
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal MelanomaNCT01979523
Recurrent Uveal...
Stage IV Uveal ...
Laboratory Biom...
Pharmacological...
Trametinib
Uprosertib
18 Years - National Cancer Institute (NCI)
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067
Advanced or Met...
Naporafenib
Dacarbazine
Temozolomide
Trametinib
18 Years - 99 YearsErasca, Inc.
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNCT05275374
Cancer
BRAF V600 Mutat...
Melanoma
Colorectal Canc...
Thyroid Cancer
Nonsmall Cell L...
XP-102
Trametinib
18 Years - Xynomic Pharmaceuticals, Inc.
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid TumorsNCT05868629
Rare Unresectab...
Non-investigati...
6 Years - Novartis
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249
KRAS G12C Mutan...
Carcinoma, Non-...
Carcinoma, Non-...
Non-Small Cell ...
Non-Small Cell ...
Nonsmall Cell L...
Colorectal Canc...
Colorectal Carc...
Colorectal Neop...
Colorectal Tumo...
Neoplasms, Colo...
JDQ443
trametinib
Ribociclib
cetuximab
18 Years - Novartis
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs ChemotherapyNCT05180825
Grade 1 Glioma
Mixed Glio-neur...
Pleomorphic Xan...
Trametinib
Vinblastine
1 Month - 25 YearsUniversity Hospital, Strasbourg, France
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02097225
BRAF V600E Muta...
BRAF V600K Muta...
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable So...
Dabrafenib
Laboratory Biom...
Onalespib
Pharmacological...
Trametinib
18 Years - National Cancer Institute (NCI)
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT01989598
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Pharmacological...
Trametinib
Uprosertib
18 Years - National Cancer Institute (NCI)
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid TumorsNCT03266159
Solid Tumours
GSK525762 Besyl...
Trametinib tabl...
18 Years - GlaxoSmithKline
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerNCT04544111
Thyroid Cancer
Thyroid Cancer,...
Papillary Thyro...
Follicular Thyr...
Hurthle Cell Tu...
Poorly Differen...
Hurthle Cell Th...
Trametinib
Dabrafenib
PDR001
18 Years - Memorial Sloan Kettering Cancer Center
Pilot Study on Trametinib for Surgical Unruptured AVMsNCT06098872
Arteriovenous M...
Trametinib tabl...
18 Years - University Health Network, Toronto
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"NCT05299580
Melanoma
dabrafenib
Trametinib
18 Years - Fondazione Melanoma Onlus
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainNCT02039947
Melanoma and Br...
Dabrafenib
Trametinib
18 Years - Novartis
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid LeukemiaNCT02016729
Advanced Malign...
Cancer
Oncology
Oncology Patien...
Acute Myeloid L...
AMG 232
Trametinib
18 Years - Kartos Therapeutics, Inc.
Treatment of NF1-related Plexiform Neurofibroma With TrametinibNCT03741101
Neurofibromatos...
Child
Neurofibroma, P...
Trametinib
1 Year - 17 YearsRegion Skane
Pan Tumor Rollover StudyNCT03899155
Cancer
Nivolumab
Ipilimumab
Cabozantinib
Trametinib
Relatlimab
Nivolumab + Rel...
Capecitabine
Bevacizumab
Temozolomide
Rucaparib
Daratumumab
Regorafinib
Leucovorin
Fluorouracil
Oxaliplatin
Enzalutamide
Sunitinib
Pemetrexed
Pembrolizumab
18 Years - Bristol-Myers Squibb
Pan Tumor Rollover StudyNCT03899155
Cancer
Nivolumab
Ipilimumab
Cabozantinib
Trametinib
Relatlimab
Nivolumab + Rel...
Capecitabine
Bevacizumab
Temozolomide
Rucaparib
Daratumumab
Regorafinib
Leucovorin
Fluorouracil
Oxaliplatin
Enzalutamide
Sunitinib
Pemetrexed
Pembrolizumab
18 Years - Bristol-Myers Squibb
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC PatientsNCT04967079
Non Small Cell ...
Trametinib
Anlotinib
18 Years - 75 YearsShanghai Chest Hospital
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaNCT02910700
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Binimetinib
Dabrafenib
Encorafenib
Laboratory Biom...
Nivolumab
Pharmacological...
Trametinib
18 Years - M.D. Anderson Cancer Center
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaNCT04310397
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Dabrafenib
Spartalizumab
Therapeutic Con...
Trametinib
18 Years - M.D. Anderson Cancer Center
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeNCT04487106
Recurrent Acute...
Recurrent Chron...
Recurrent Myelo...
Refractory Acut...
Refractory Chro...
Refractory Myel...
Azacitidine
Trametinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsNCT02684058
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Ipon...
Dabrafenib
trametinib
Carboplatin
Vincristine
12 Months - 17 YearsNovartis
Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in SpainNCT02439411
Malignant Melan...
Malignant Melan...
Trametinib
18 Years - Grupo Español Multidisciplinar de Melanoma
Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary CraniopharyngiomaNCT05525273
Craniopharyngio...
Oral dabrafenib...
18 Years - Skane University Hospital
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated PatientsNCT02296996
Malignant Melan...
Dabrafenib + Tr...
18 Years - Universitair Ziekenhuis Brussel
Melanoma Metastasized to the Brain and SteroidsNCT03563729
Malignant Melan...
Pembrolizumab I...
Ipilimumab Inje...
Nivolumab Injec...
Encorafenib
Binimetinib
Dabrafenib
Trametinib
18 Years - Herlev Hospital
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaNCT05849662
Leukemia, Juven...
JMML
JCML
Neurofibromatos...
CBL Syndrome
Trametinib
Azacitidine
Fludarabine
Cytarabine
1 Month - 21 YearsTherapeutic Advances in Childhood Leukemia Consortium
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)NCT04185883
Advanced Solid ...
Kirsten Rat Sar...
Sotorasib
Trametinib
RMC-4630
Afatinib
Pembrolizumab
Panitumumab
Carboplatin, pe...
Atezolizumab
Palbociclib
MVASI® (bevaciz...
TNO155
IV Chemotherapy...
IV Chemotherapy...
BI 1701963
AMG 404
Everolimus
18 Years - 100 YearsAmgen
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaNCT01989585
Clinical Stage ...
Clinical Stage ...
Malignant Solid...
Metastatic Mela...
Unresectable Me...
Biopsy
Biospecimen Col...
Computed Tomogr...
Dabrafenib
Echocardiograph...
Laboratory Biom...
Magnetic Resona...
Multigated Acqu...
Navitoclax
Pharmacological...
Trametinib
18 Years - National Cancer Institute (NCI)
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsNCT02079740
Metastatic Mali...
Refractory Mali...
Unresectable Ma...
Biopsy
Biospecimen Col...
Computed Tomogr...
Magnetic Resona...
Navitoclax
Positron Emissi...
Trametinib
18 Years - National Cancer Institute (NCI)
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerNCT04739566
Thyroid Gland A...
Dabrafenib
Trametinib
18 Years - Saint Petersburg State University, Russia
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal CancerNCT02399943
Colorectal Canc...
KRAS Wildtype
NRAS Wildtype
BRAF Wildtype
Trametinib
Panitumumab
18 Years - University Health Network, Toronto
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaNCT03091257
Multiple Myelom...
Dabrafenib
Trametinib
18 Years - Massachusetts General Hospital
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain MetastasesNCT02974803
Melanoma
Brain Metastase...
Dabrafenib
Trametinib
18 Years - Canadian Cancer Trials Group
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Lipo...
Neurofibromatos...
dabrafenib
trametinib
1 Year - Novartis
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsNCT01827384
Advanced Malign...
Adavosertib
Carboplatin
Everolimus
Temozolomide
Trametinib
Veliparib
18 Years - National Cancer Institute (NCI)
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaNCT05849662
Leukemia, Juven...
JMML
JCML
Neurofibromatos...
CBL Syndrome
Trametinib
Azacitidine
Fludarabine
Cytarabine
1 Month - 21 YearsTherapeutic Advances in Childhood Leukemia Consortium
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067
Advanced or Met...
Naporafenib
Dacarbazine
Temozolomide
Trametinib
18 Years - 99 YearsErasca, Inc.
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerNCT02881242
Hormone-Resista...
Metastatic Pros...
Recurrent Prost...
Stage IV Prosta...
Laboratory Biom...
Quality-of-Life...
Trametinib
18 Years - Jonsson Comprehensive Cancer Center
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete ResectionNCT04666272
Melanoma
dabrafenib
trametinib
18 Years - 100 YearsNovartis
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Lipo...
Neurofibromatos...
dabrafenib
trametinib
1 Year - Novartis
A Study of GSK2256098 and Trametinib in Advanced Pancreatic CancerNCT02428270
Pancreatic Canc...
Adenocarcinoma
GSK2256098
Trametinib
18 Years - University Health Network, Toronto
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibNCT03076164
Lung Adenocarci...
Lung Cancer
Lung Cancer Met...
Lung Cancer Sta...
Recurrent Lung ...
Recurrent Lung ...
Trametinib
Erlotinib
18 Years - Memorial Sloan Kettering Cancer Center
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesNCT03551626
Malignant Melan...
Dabrafenib
Trametinib
18 Years - Novartis
Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasNCT03631953
Meningioma
Trametinib
Alpelisib
Blood sample
MRI
18 Years - Assistance Publique Hopitaux De Marseille
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)NCT01928940
Solid Tumours
dabrafenib
trametinib
20 Years - GlaxoSmithKline
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaNCT05440942
Pancreatic Duct...
Trametinib
Ruxolitinib
Retifanlimab
18 Years - University of Miami
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaNCT03754179
Melanoma
Dabrafenib
Trametinib
Hydroxychloroqu...
18 Years - Universitair Ziekenhuis Brussel
MCS110 With BRAF/MEK Inhibition in Patients With MelanomaNCT03455764
Melanoma
MCS110
Dabrafenib
Trametinib
18 Years - Dana-Farber Cancer Institute
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaNCT02967692
Melanoma
Spartalizumab
Placebo
Dabrafenib
Trametinib
18 Years - Novartis
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerNCT04294160
BRAF V600 Color...
Dabrafenib
LTT462
Trametinib
LXH254
TNO155
Spartalizumab
Tislelizumab
18 Years - Novartis
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsNCT05876806
Cancer
Dabrafenib
Trametinib
19 Years - Seoul St. Mary's Hospital
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid LeukemiaNCT01907815
Recurrent Adult...
Untreated Adult...
Akt Inhibitor G...
Laboratory Biom...
Trametinib
18 Years - National Cancer Institute (NCI)
Treatment of NF1-related Plexiform Neurofibroma With TrametinibNCT03741101
Neurofibromatos...
Child
Neurofibroma, P...
Trametinib
1 Year - 17 YearsRegion Skane
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by SurgeryNCT03148275
Locally Advance...
Metastatic Epit...
Unresectable Ep...
Questionnaire A...
Trametinib
15 Years - National Cancer Institute (NCI)
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadNCT03377361
Colorectal Canc...
Colorectal Tumo...
Colorectal Carc...
Colorectal Neop...
Nivolumab
Trametinib
Ipilimumab
Regorafenib
18 Years - Bristol-Myers Squibb
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic CancerNCT03825289
Metastatic Panc...
Stage II Pancre...
Stage IIA Pancr...
Stage IIB Pancr...
Stage III Pancr...
Stage IV Pancre...
Unresectable Pa...
Hydroxychloroqu...
Trametinib
18 Years - University of Utah
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCNCT03333343
EGFR-mutant Non...
EGF816
trametinib
ribociclib
LXH254
INC280
gefitinib
18 Years - Novartis
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)NCT02130466
Melanoma
Solid Tumors
Pembrolizumab
Dabrafenib
Trametinib
Placebo
18 Years - Merck Sharp & Dohme LLC
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNCT04507919
Small Cell Lung...
Dabrafenib
Trametininb
18 Years - 99 YearsNovartis
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-PaclitaxelNCT01192165
Cancer
Trametinib (GSK...
Docetaxel
Erlotinib
Pemetrexed
Carboplatin
nab-Paclitaxel
Cisplatin
18 Years - GlaxoSmithKline
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibNCT02382549
Melanoma
BRAF inhibitor
6MHP
MEK inhibitor
18 Years - University of Virginia
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibNCT02357732
Metastatic Mela...
Nivolumab
Trametinib
Dabrafenib
18 Years - University of Pittsburgh
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibNCT02140840
Multiple Myelom...
Trametinib
18 Years - University of Arkansas
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationNCT04201457
Low Grade Gliom...
High Grade Glio...
Low Grade Gliom...
Dabrafenib
Trametinib
Hydroxychloroqu...
1 Year - 30 YearsPediatric Brain Tumor Consortium
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsNCT01721603
BRAFV600E Melan...
Dabrafenib
Gamma Knife Rad...
Trametinib
18 Years - University of California, San Francisco
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 MutationsNCT02296112
Recurrent Melan...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
trametinib
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs ChemotherapyNCT05180825
Grade 1 Glioma
Mixed Glio-neur...
Pleomorphic Xan...
Trametinib
Vinblastine
1 Month - 25 YearsUniversity Hospital, Strasbourg, France
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationNCT02231775
Stage IIIB Cuta...
Stage IIIC Cuta...
Dabrafenib
Laboratory Biom...
Therapeutic Con...
Trametinib
18 Years - M.D. Anderson Cancer Center
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaNCT01767454
Solid Tumours
Dabrafenib
Trametinib
Ipilimumab
18 Years - GlaxoSmithKline
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerNCT03975231
BRAF NP_004324....
BRAF V600K Muta...
Thyroid Gland A...
Dabrafenib
Intensity-Modul...
Trametinib
18 Years - City of Hope Medical Center
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCNCT04452877
Carcinoma, Non-...
Dabrafenib
Trametinib
18 Years - Novartis
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).NCT04566133
Bile Duct Cance...
Biliary Cancer
Biliary Tract N...
Cholangiocarcin...
Trametinib
Hydroxychloroqu...
18 Years - National Institutes of Health Clinical Center (CC)
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsNCT02684058
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Ipon...
Dabrafenib
trametinib
Carboplatin
Vincristine
12 Months - 17 YearsNovartis
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid CancerNCT03244956
Metastatic Radi...
Trametinib
Dabrafenib
131I
rhTSH
18 Years - Gustave Roussy, Cancer Campus, Grand Paris
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)NCT04111458
Solid Tumors, K...
BI 1701963
Trametinib
18 Years - Boehringer Ingelheim
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibNCT02140840
Multiple Myelom...
Trametinib
18 Years - University of Arkansas
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaNCT05440942
Pancreatic Duct...
Trametinib
Ruxolitinib
Retifanlimab
18 Years - University of Miami
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: